Clenbuterol to Target DUX4 in FSHD

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
Jeffrey Statland
Study ID
NCT06721299
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Muscular Dystrophy, Facioscapulohumeral

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Clenbuterol — DRUG
    Beta-Agonist

Study Details

The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.

Key Dates

Start date
Jun 25, 2025
Status verified
Feb 2026
Primary completion
Feb 29, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Clenbuterol Cohort 1
    20 mcg taken orally twice daily
  • Experimental: Clenbuterol Cohort 2
    40 mcg taken orally twice daily
  • Experimental: Clenbuterol Cohort 3
    60 mcg taken orally twice daily

Primary Outcome Measure

Frequency of Clenbuterol-related adverse reactions [ Time Frame: from baseline to 6 month visit ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of Kansas Medical CenterKansas CityKansas66160
Rebecca Clay, BS
[email protected]
913-945-9936
Jeffrey Statland (PRINCIPAL_INVESTIGATOR)
University of Rochester Medical CenterRochesterNew York14642
Leann Lewis, MSGC
[email protected]
585-275-7680
Brianna Brun (PRINCIPAL_INVESTIGATOR)
University of WashingtonSeattleWashington98104
Lilly Young
[email protected]
206-616-5957
Leo Wang

Find similar trials in Kansas City, KS

By research site
University of Kansas Medical Center· Kansas City, KSUniversity of Rochester Medical Center· Rochester, NYUniversity of Washington· Seattle, WA

Related Studies